Patent Issued for Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (USPTO 11851434).

A patent has been issued for substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors. These compounds have been found to inhibit the activity of the Rearranged during Transfection (RET) kinase, which is involved in the development and maintenance of various tissues and cell types. The compounds have potential applications in the treatment of diseases that can be treated with a RET kinase inhibitor, including certain types of cancer. The patent provides information on the chemical structure of the compounds, their pharmaceutical compositions, and methods of inhibiting cell proliferation using these compounds. [Extracted from the article]